| Literature DB >> 24778153 |
Lili Wang1, Alex K Shalek2, Mike Lawrence3, Ruihua Ding2, Jellert T Gaublomme2, Nathalie Pochet3, Petar Stojanov3, Carrie Sougnez3, Sachet A Shukla1, Kristen E Stevenson4, Wandi Zhang1, Jessica Wong1, Quinlan L Sievers1, Bryan T MacDonald5, Alexander R Vartanov6, Natalie R Goldstein6, Donna Neuberg4, Xi He5, Eric Lander3, Nir Hacohen7, Aviv Regev3, Gad Getz3, Jennifer R Brown8, Hongkun Park2, Catherine J Wu9.
Abstract
One major goal of cancer genome sequencing is to identify key genes and pathways that drive tumor pathogenesis. Although many studies have identified candidate driver genes based on recurrence of mutations in individual genes, subsets of genes with nonrecurrent mutations may also be defined as putative drivers if they affect a single biological pathway. In this fashion, we previously identified Wnt signaling as significantly mutated through large-scale massively parallel DNA sequencing of chronic lymphocytic leukemia (CLL). Here, we use a novel method of biomolecule delivery, vertical silicon nanowires, to efficiently introduce small interfering RNAs into CLL cells, and interrogate the effects of 8 of 15 mutated Wnt pathway members identified across 91 CLLs. In HEK293T cells, mutations in 2 genes did not generate functional changes, 3 led to dysregulated pathway activation, and 3 led to further activation or loss of repression of pathway activation. Silencing 4 of 8 mutated genes in CLL samples harboring the mutated alleles resulted in reduced viability compared with leukemia samples with wild-type alleles. We demonstrate that somatic mutations in CLL can generate dependence on this pathway for survival. These findings support the notion that nonrecurrent mutations at different nodes of the Wnt pathway can contribute to leukemogenesis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24778153 PMCID: PMC4133483 DOI: 10.1182/blood-2014-01-552067
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113